CCTG at ESMO 2024

The European Society for Medical Oncology Congress (ESMO) 2024 congress was held September 13-17 in Barcelona, Spain and CCTG was there!  

CCTG related presentations and posters

1. BR.31 oral presentation: A double-blind, placebo-controlled, randomized phase 3 trial of adjuvant durvalumab in completely resected non-small-cell lung cancer > https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/show/session/17
2. GA.1 TOPGEAR oral presentation: investigated adding concurrent radiotherapy to standard treatment to determine if it would improve pathological complete response rates and ultimately overall survival of these patients with resectable gastric and gastro-esophageal junction adenocarcinoma >  https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/show/session/43
3. MAC.20 Alliance A011401 oral presentation: A pre-planned secondary analysis of the BWEL trial evaluating the impact of the WLI on changes in MVPA > https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/show/session/195
4. OV.26 ICON9 oral presentation: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy > ;https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/show/session/166
5. CO.28 poster presentation: Neoadjuvant chemotherapy, excision, and observation for early rectal cancer, results after minimum 3 years follow up > https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal_2/presentation/list?q=CCTG
6. 2 PR.17 posters: https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal_2/presentation/list?q=enzamet
   • 1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
   • 1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)